FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
Leqembi is an antibody treatment that targets brain plaque associated with the mind-robbing disease. It is administered intravenously twice a month and slowed the progression of early Alzheimer's disease by 27% in clinical trials. However, it also carries risks of brain swelling and bleeding and costs $26,500 a year., access to the treatment is virtually nonexistent right now.
It will take time to set up those studies; health-care providers and research institutes have to be recruited, and patients would also have to agree to participate. The health-care system would also need more capacity to administer the diagnostic tests and infusions needed to administer the drug. Join CNBC's Healthy Returns on March 29, where we'll convene a virtual gathering of CEOs, scientists, investors and innovators in the health-care space to reflect on the progress made today to reinvent the future of medicine. Plus, we'll have an exclusive rundown of the best investment opportunities in biopharma, health-tech and managed care. Learn more and register today:
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eisai, Biogen say FDA grants priority review for Alzheimer's drug LecanemabJapanese drugmaker Eisai Co Ltd and its U.S. partner Biogen Inc said on Monday that the U.S. Food and Drug Administration granted priority review for traditional approval of their Alzheimer's treatment Lecanemab.
Read more »
Elon Musk’s bid to implant chips into human brains shot down by FDANeuralink CEO Elon Musk’s request to implant brain chips in human trials was rejected by the Biden administration .
Read more »
FDA cracks down on animal tranquilizer as overdose deaths and amputations soarThe FDA will restrict imports of the animal tranquilizer, Xylazine, known as 'Tranq' on the street. The drug has now infiltrated much of the fentanyl and heroin supply in the U.S.
Read more »
Colorado pharmacies caught in the middle of abortion battle after FDA decisionPharmacy chains in Colorado are caught in the middle of the abortion battle after the Food and Drug Administration expanded access to abortion pills earlier this year.
Read more »
Drug shipments to U.S. hold cheap generic Viagra, not opioids feared by FDAThe FDA's data from recent years on its seizure of packages containing drugs coming through international mail provides scant evidence that a significant number of opioids enter this way.
Read more »
Food fight: FDA is redefining ‘healthy’ and food industry is pushing backLess saturated fat, less sodium, less added sugar -- manufacturers say almost no packaged foods would qualify under the agency’s new rules
Read more »